Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
Author:
Affiliation:
1. Department of Respiratory MedicinePeking Union Medical College Hospital Beijing China
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13302
Reference27 articles.
1. Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival
2. Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non‐small‐cell lung cancer (ANSCLC) of adenocarcinoma (ADC) and non‐ADC histology: IGNITE study;Han B;Ann Oncol,2015
3. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy;Molecules;2024-03-23
2. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-02
3. An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review;Journal of Biomolecular Structure and Dynamics;2023-05-09
4. Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer;Biochemical Pharmacology;2022-11
5. A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship;Frontiers in Chemistry;2022-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3